Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Pancreatic Neoplasms 47Carcinoma, Non-Small-Cell Lung 14Neoplasm Metastasis 11Neoplasms 9Colorectal Neoplasms 8Breast Neoplasms 8Triple Negative Breast Neoplasms 7Lung Neoplasms 6Sarcoma 5Melanoma 4Esophageal Neoplasms 3Cholangiocarcinoma 3Brain Neoplasms 3Thyroid Neoplasms 2Stomach Neoplasms 2Squamous Cell Carcinoma of Head and Neck 2Small Cell Lung Carcinoma 2Pancreatic Diseases 2Gastrointestinal Neoplasms 2Carcinoma 2Biliary Tract Neoplasms 2Advanced Solid Tumors 2Adenocarcinoma 2Urinary Bladder Neoplasms 1Tongue Neoplasms 1TNBC 1Solid Tumor 1Sarcoma, Ewing 1Rhabdomyosarcoma 1Recurrence 1

Interventions

Gemcitabine 3Irinotecan 2Albumin-Bound Paclitaxel 2ibrutinib 1adavosertib 1Paclitaxel 1PEGPH20 1Oxaliplatin 1Leucovorin 1Fluorouracil 1Docetaxel 1Cisplatin 1Capecitabine 1130-nm albumin-bound paclitaxel 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1/2 × Metastatic Pancreatic Adenocarcinoma × 130-nm albumin-bound paclitaxel × Clear all
NCT02194829 2023-04-25

Paclitaxel Albumin-Stabilized Nanoparticle Formulation and Gemcitabine Hydrochloride With or Without WEE1 Inhibitor AZD1775 in Treating Patients With Previously Untreated Pancreatic Cancer That Is Metastatic or Cannot Be Removed by Surgery

National Cancer Institute (NCI)

Phase 1/2 Completed
8 enrolled 9 charts
Gastrointestinal

Metastatic Pancreatic Adenocarcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡